Clinical trials: pills and oral medicines
Relapsing Multiple Sclerosis
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple…
- Trial name
- NCT06846281
- Testing
- Remibrutinib oral treatment, Ocrelizumab
- Where
- 131 sites in United States, Argentina and 17 more
- Volunteers
- 400 people
- Sponsor
- Novartis Pharmaceuticals
Essential Arterial Hypertension
Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension
This is a phase III, non-inferiority, randomized, double-blind, double-dummy, active-controlled, multicenter study to compare the efficacy and safety of N0877 versus double combination with already established efficacy on…
- Trial name
- ATHESA (NCT06608472)
- Testing
- N0877, Benicar HCT ® Tablets 40 mg/25 mg
- Sponsor
- Eurofarma Laboratorios S.A.
Renal Impairment
Renal Impairment Pharmacokinetics (PK) Trial of Afabicin
The primary purpose of this study is to assess the effect of renal impairment on the PK of afabicin desphosphono after a single oral 80 milligrams (mg) or intravenous (IV) 55 mg dose of afabicin.
- Trial name
- NCT07758608
- Testing
- Afabicin Oral, Afabicin IV
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Debiopharm International SA
Migraine
Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine
A phase III study, multicenter, double-blind, double-dummy, randomized, single-dose, placebo-controlled study to evaluate the efficacy and safety of Rizatriptan-Naproxen (10/550 mg) in the acute treatment of migraine.
- Trial name
- RELIEF (NCT04384367)
- Testing
- Rizatriptan 10 mg + Naproxen 550mg, Maxalt 10Mg Tablet, Flanax 550mg
- Where
- 2 sites in Brazil
- Volunteers
- 2,068 people
- Sponsor
- Eurofarma Laboratorios S.A.
Solid Tumor, Ovarian Cancer
A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
A study to evaluate the safety, tolerability, pk, and efficacy of XS-02 capsules in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Ovarian Cancer, Breast Cancer, Endometrial Cancer
- Trial name
- NCT06531486
- Testing
- XS-02 capsules
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Adjunct in the Treatment of Depressive Disorder
A Randomized, Open-Label, 52-Week Extension Study to Evaluate the Maintenance of Remission, Relapse Prevention, and Long-Term Safety of CreNeuroS™ in Patients With Major Depressive Disorder Who Achieved Remission Following an 8-Week Parent Study
This multicenter, randomized, open-label extension study will evaluate the maintenance of remission, relapse prevention, long-term clinical outcomes, and safety of CreNeuroS™ in participants with Major Depressive Disorder (MDD)…
- Trial name
- NCT07893002
- Testing
- No intervention, CreNeuroS™ CNS Fish Oil Plus Softgels, 1 capsule orally once daily, CreNeuroS™ CNS Fish Oil Plus Softgels, 2 capsule orally once daily
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Sichuan Credit Pharmaceutical Co., Ltd.
Breast Cancer
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
TOL2506A (OVELIA) is a Phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 in suppressing ovarian function in premenopausal women with HR+, HER2-negative breast cancer and men with HR+ breast cancer.
- Trial name
- NCT05645536
- Testing
- TOL2506, Tamoxifen, Letrozole tablets
- Where
- 46 sites in United States, Argentina and 4 more
- Volunteers
- 250 people
- Sponsor
- Tolmar Inc.
Autosomal Recessive Polycystic Kidney (ARPKD)
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
To evaluate the pharmacodynamics and safety of tolvaptan in pediatric subjects with ARPKD
- Trial name
- NCT04782258
- Testing
- Tolvaptan Suspension, Tolvaptan Tablets
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 20 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Chronic Heart Failure With Preserved Ejection Fraction
Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction
Main objective: To evaluate the efficacy, safety and clinical dose exploration of Qishen Yiqi dripping pills in the treatment of chronic heart failure with preserved ejection fraction.
- Trial name
- NCT04944706
- Testing
- Qishen Yiqi dripping pills 4 bags/time
- Where
- 16 sites in China
- Volunteers
- 225 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Chronic Heart Failure With Reduced Ejection Fraction
Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure
This study will evaluate the efficacy and safety and the best effective dose of QiShen YiQi Dripping Pills in the treatment of chronic heart failure with decreased ejection fraction of CHD (Qi deficiency and blood stasis…
- Trial name
- NCT04983043
- Testing
- Low dose QiShen YiQi Dripping Pills 3 bags, High dose QiShen YiQi Dripping Pills 3 bags
- Where
- 23 sites in China
- Volunteers
- 228 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Smoking Cessation, Nicotine Replacements Therapy
A Study of Nicotine Orodispersible Tablet on Craving Relief of Male and Female Smoker Volunteers
The objective of the study is to evaluate the relief of momentary urge to smoke at pre-specified early post-dose time points after administration of Nic ODT compared to Placebo ODT.
- Trial name
- Zippy PD (NCT07893158)
- Testing
- Nicotine Mint Oro Dispersible Tablet (Nic ODT)
- Where
- Canada
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- McNeil AB
Healthy Volunteers
A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults
The purpose of this study is to evaluate whether blood levels of sonrotoclax after administration of a tablet for oral suspension are similar to those observed with the current sonrotoclax tablet.
- Trial name
- NCT07628881
- Testing
- Sonrotoclax Tablet for Oral Suspension, Sonrotoclax Tablet
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Breast Cancer
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
This is a phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 to suppress ovarian function in premenopausal women with HR+, HER2-negative breast cancer.
- Trial name
- OVELIA (NCT04906395)
- Testing
- TOL2506, Tamoxifen, Letrozole Tablets
- Where
- 59 sites in United States, Argentina and 5 more
- Volunteers
- 250 people
- Sponsor
- Tolmar Inc.
Chronic Weight Management
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With Obesity or Overweight
This is a randomized, placebo-controlled, double-blind, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of ASC36 Tablets for Oral Use in Adult…
- Trial name
- NCT07893106
- Testing
- ASC36 tablets, for oral use
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Chemotherapy-induced Anemia, Non-Myeloid Malignancy
HEC53856 Tablets for Chemotherapy-induced Anemia in Non-myeloid Malignancies
A Phase II clinical trial to evaluate the efficacy and safety of different dosing regimens of HEC53856 tablets compared to rHuEPO injection in participants of the CIA trial.
- Trial name
- NCT07891377
- Testing
- HEC53856 tablet, rHuEPO injection
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Diabetic Kidney Disease
Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)
This study will evaluate the efficacy and Safety of QiShen YiQi Dripping Pills in the treatment of Diabetic Kidney Disease (syndrome of Qi deficiency with blood stasis)
- Trial name
- NCT06006689
- Testing
- Low dose Qishen Yiqi Dripping Pills 3 bags, High dose Qishen Yiqi Dripping Pills 3 bags
- Where
- 16 sites in China
- Volunteers
- 228 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Heart Failure
Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre
This trial will evaluate the efficacy and safety of Qishen Yiqi Dripping Pills in treatment of Chronic Heart Failure with reduced ejection fraction resorted from Coronary Heart Disease (Syndrome of Qi Deficiency with Blood…
- Trial name
- NCT07687186
- Testing
- Qishen Yiqi Dripping Pills 2 bags
- Where
- 60 sites in China
- Volunteers
- 636 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Edema Due to Heart Failure or Cirrhosis
A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Spironolactone Oral Suspension in Pediatric Patients
This is a 2-part, 2 periods per part, open-label study with spironolactone oral suspension in pediatric patients with edema due to HF or hepatic cirrhosis.
- Trial name
- NCT06021860
- Testing
- Spironolactone Oral Suspension
- Volunteers
- 96 people
- Sponsor
- CMP Development, LLC
SSM, Mastocytosis, Indolent
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 clinical study comparing the safety and efficacy of bezuclastinib (CGT9486) plus best supportive care (BSC) with placebo plus BSC in patients with…
- Conditions
- SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis
- Trial name
- NCT05186753
- Testing
- Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B)
- Where
- 57 sites in United States, Australia and 13 more
- Volunteers
- 237 people
- Sponsor
- Cogent Biosciences, Inc.
Bacterial Vaginosis (BV)
WST03 Capsule Combined With Metronidazole for Bacterial Vaginosis
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial enrolling approximately 150 pre-menopausal women with bacterial vaginosis (BV). Participants will be randomized 1:1:1 to three groups.
- Trial name
- NCT07888699
- Testing
- High-dose WST03 Vaginal Capsule Metronidazole, Low-dose WST03 Vaginal Capsule Metronidazole
- Where
- 14 sites in China
- Volunteers
- 150 people
- Sponsor
- SPH Sine Pharmaceutical Laboratories Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.